RIO-Diabetes - RIO-Diabetes

Description:

The goal of the trial was to evaluate the efficacy and safety of rimonabant, a selective cannabinoid type 1 (CB1) receptor antagonist, compared with placebo for weight reduction among overweight or obese patients with type 2 diabetes.